key: cord-0682972-05xedq1l
authors: Raoult, Didier; Hsueh, Po-Ren; Stefania, Stefani; Rolain, Jean-Marc
title: VSI: COVID-19 Therapeutic
date: 2020-03-07
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.105937
sha: 17de15d04f7a7643550666d2f0da773f5b7dc95c
doc_id: 682972
cord_uid: 05xedq1l

nan

We are publishing a special issue dedicated to the coronavirus, in all its aspects of management and treatment. Indeed, in the 21st century, it is necessary to share data as quickly as possible, including the publication of preliminary data, so that in the time of care and management, the maximum should be done to help infected patients and decision-makers in strategies to fight this new virus [1] . This responds to recent recommendations and has the advantage over the pre-prints, which are currently available, of having been urgently reviewed by competent reviewers in the field, to assess their credibility. Thus, in order to meet modern needs for dissemination of data on emerging pathogens and disease, the combination of speed and credibility assessment becomes essential elements in the response against epidemics.

The response to the creation of a such special issue also takes into account the fact that not only the disease is emerging, but that it originates from "emerging countries", and giving everyone access to preliminary data from the Far East is a necessity for patient management in other areas. In particular, we see that a controversy has arisen in the use of repositioning treatments, such as chloroquine [2, 3] , for coronavirus, which justifies calling on those who have the most experience with this disease to communicate to the rest of the scientific world, in order to shed light on the choices to come. L'idea della pubblicazione di questo numero speciale tiene conto del fatto che non solo sta emergendo una nuova malattia, ma che questa proviene dai "paesi emergenti" facendo diventare importantissimo l'accesso ai dati preliminari dall'Estremo Oriente, In modo da far condividere la loro esperienza di gestione ai colleghi di altre aree del pianeta. In particolare, stiamo assistendo ad una controversia nell'uso e nel riposizionamento di alcuni trattamenti, un esempio è la clorochina [2, 3] , per le infezioni sostenute da coronavirus, giustificando quindi il nostro appello verso coloro che hanno acquisito esperienze con questa malattia al fine di comunicare questa loro conoscenza al resto del mondo.Tutto questo aiuterà a far luce sulle scelte in divenire.

Coronavirus: keep sharing research

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19